Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Koedam

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|November 8, 1986
[Current insights in factor VIII biology]J J Sixma, R J Hamer, J Koedam
In Vivo (Athens, Greece)|July 1, 1990
Radiosensitivity of different human tumor lines grown as xenografts determined from growth delay and survival dataJ H Schwachöfer, J Hoogenhout, H B Kal, et al.
The Journal of Investigative Dermatology|November 1, 1984
Fucosyl glycopeptide profiles of keratinocytes from various epithelial tissues of the rabbit in relation to differentiation in vivo and in vitroP E van Erp, M Bergers, R M de Grood, et al.
Leukemia Research|May 1, 2013
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blastsL H van der Helm, N J G M Veeger, M van Marwijk Kooy, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nederlands Tijdschrift Voor Geneeskunde|November 8, 1986
[Current insights in factor VIII biology]J J Sixma, R J Hamer, J Koedam
In Vivo (Athens, Greece)|July 1, 1990
Radiosensitivity of different human tumor lines grown as xenografts determined from growth delay and survival dataJ H Schwachöfer, J Hoogenhout, H B Kal, et al.
The Journal of Investigative Dermatology|November 1, 1984
Fucosyl glycopeptide profiles of keratinocytes from various epithelial tissues of the rabbit in relation to differentiation in vivo and in vitroP E van Erp, M Bergers, R M de Grood, et al.
Leukemia Research|May 1, 2013
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blastsL H van der Helm, N J G M Veeger, M van Marwijk Kooy, et al.
Pageof 1